Revenue +21.6%, but PAT crashed 68.7% due to ₹114Cr merger costs

₹1,310.7 Cr reported, +21.6% YoY; matches claim

Reported PAT only ₹29.3 Cr, down 68.7% YoY after ₹114 Cr exceptional merger costs

EBITDA margin of 21.1% claimed; delivered OPM 11.4%; exceptional costs not in EBITDA

Metrics support volume-driven growth; occupancy to 64% plausible

Exceptional growth on low base; actual MVT contribution to revenue not disclosed

Shift from Aster standalone (₹1,311 Cr, ₹277 Cr EBITDA) to merged ₹2,597 Cr proforma revenue. Quality Care +19% YoY, +32% EBITDA growth. Organization restructure underway (3 India CEOs, maturity-based reporting).

Reported PAT ₹29.3 Cr vs normalized ₹125 Cr. Prior Q4 FY26 guidance implied continued margin strength; this quarter's NPM 2.2% shows cost headwinds masked by exceptional items.

Management stated 'synergies haven't played out yet; started this month.' 10-15% EBITDA uplift (₹150-200 Cr) is committed, but Q1 shows zero benefit. No synergies in earnings yet.

Mature (73% revenue, 19% growth, 30% EBITDA margin), Focus (15%, 16% growth, teens EBITDA), Emerging (12%, 63% growth, 12.4% EBITDA). Shift away from Aster/QCIL brand silos; harder to track legacy unit performance.

Geographic continuity and maturity-based structure overlaid. Four maturity cuts (Mature 73%, Focus 15%, Emerging 12%, Underperforming small). Will report by maturity, not primarily by brand; 3 India CEOs managing regions.

Synergies, operational/clinical incidence, strategic roadmap. On margins: no quarter-on-quarter guidance; still targeting 24-25% in 2-3 years post-merger.

Synergies haven't played out; started this month. 10-point synergy wheel: indirect procurement (large), revenue synergies, clinical talent. 10-15% incremental EBITDA by end of FY27 starting this year.

DBS program (India's best in Kochi) can now serve Kerala/Hyderabad. Liver transplant centralized across 39 units. Clinical team leverage across network replaces local duplication.

Low base and catch-up. Improved sales structure, CRM, lead tracking. Clinical outcomes benchmark globally; patients refer. MVT contribution still low; target is double-digit share in 2-3 years (currently mid-single digit).

Competition always evolves. Merged entity capability level up; clinical fraternity biased toward us due to ethics and outcomes. Gain preference in every micro-market.

Soft periods in competitive markets; return over 1-2 quarters. Lost general surgery team 9 months back; 4 months later they rejoined—shows credibility. Double-digit to mid-teen growth sustainable with 5-6% volume and 7-8% ARPP.

Will report by maturity going forward; will still share geographical top-line if requested. Maturity framework is critical lens for EBITDA visibility.

Kasaragod broke even in 9 months, 2-3% EBITDA. Whitefield strong. Bangalore: added 18 doctors in Q1 alone; all 3 Aster hospitals hit all-time high revenue in June. 16% growth recovery after single-digit.

Focus on growth rate (50%+ sustainability) vs contribution. Mid-single-digit to double-digit share in 2-3 years. ₹65M base; growing 65% now.

Committed to 10-15%. ₹150-200 Cr absolute. Upside always there with growth, but near-term target is 10-15%. That's a very good quantum.

Won't call it FY29 exactly; it's a transition. Currently 22%+. With growth, targeting 24-25% by 2-3 years. Good exit in 2027; between 2028-2029 reach targets.

Bhubaneswar big project. Raipur cancer center inaugurating mid-August. Kottayam addition 2028. Nagercoil, Banjara Hills, Nampally, Shifa small adds by 2028. Will provide detailed breakup offline.

Management confident in 5-6% volume and 7-8% ARPP growth to sustain double-digit overall growth toward 24-25% EBITDA margins. No quarterly guidance.

Currently 22%+ (Aster 21.1%, combined 22.2%). Synergies (10-15% incremental EBITDA) plus organic leverage to drive expansion. No FY27-specific margin guidance.

Trivandrum (H2 FY27, Jan 2027), Hyderabad (Apr 2027), Sarjapur Phase 1 (H2 FY28). Annual run-rate ~1,200 beds FY27-FY28.

Management committed to 10-15% incremental EBITDA (₹150-200 Cr) from synergies starting FY27, but synergies 'haven't played out yet.' Merger just closed July 1. Organizational structure (3 India CEOs, matrixed setup) not fully finalized; reporting framework evolving. If synergies slip or scale slower, margin recovery to 24-25% by FY29 at risk.

Reported PAT ₹29.3 Cr is down 68.7% YoY despite 21.6% revenue growth. NPM crashed to 2.2% from prior ~5%. Exceptional merger costs ₹114 Cr (8.7% of revenue) explain Q1 hit, but underlying cost structure appears heavier. Margin recovery to 25% by FY29 depends entirely on synergies kicking in AND volume/ARPP growth sustaining at 5-6% and 7-8% respectively.

Bangalore saw single-digit growth in FY26 due to doctor attrition and new competitor entry; recovered to 16% in Q1 FY27 after hiring 18 doctors and turnover stabilization. Kerala faced leadership changes in Q4 FY25 (5% negative growth) but recovered to 25% in Q1 FY27. Recovery is strong, but competitive pressure from unspecified new entrants remains; sustainability at 'double-digit to mid-teen' depends on clinical brand and talent retention.

Medical Value Travel (MVT) contribution is still <2% of revenue despite 62% YoY growth on low base. Management targeting mid-single to double-digit share by 2028-29. If MVT doesn't scale or macroeconomic headwinds hit international patient volumes (Middle East recession, visa restrictions), upside growth story falters. No near-term upside from diagnostics or pharmacy.

Ambitious 4,170-bed expansion over 3-4 years (₹1,200+ beds FY27-FY28) with 53% brownfield. Kasaragod and Whitefield greenfield track record is strong (profitable in 9 and 4 months), but portfolio expansion at this pace in competitive markets carries gestation risk. Trivandrum (Jan 2027), Hyderabad (Apr 2027), Sarjapur (H2 FY28) timelines critical. Capex guidance not quantified; any cost overruns or delays could pressure ROCE and margin targets.